Brian A. Boyle

from The AIDS Reader

The flood of developments in HIV research continues, and new data have recently been presented regarding some important issues in HIV therapeutics. These include what HAART regimen to start with, when that regimen should be started, and the impact and efficacy of simplified HIV therapy.

This column will provide summaries and analyses of these recent data. Data regarding the treatment of important coinfections, including herpes simplex virus infection, hepatitis B, and hepatitis C, will be discussed in Part 2.

Part 1 full text at:
http://www.medscape.com/viewarticle/444892